BioElectronics Earns CE Mark for the ActiPatch and RecoveryRx — Drug-Free Pain Therapy Devices

Opens the Sales Market for 33+ Additional Countries

FREDERICK, MD, Nov. 12, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that it has received the CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx® Pulsed Shortwave Therapy (PSWT) medical devices.

The ActiPatch is indicated for the treatment of general musculoskeletal/soft-tissue pain, while the RecoveryRx is indicated for the treatment of postoperative pain. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark.

Keith Nalepka, VP Sales and Marketing for BioElectronics, said: “This is the latest in a series of wins for the Company. The CE mark will allow us to resume fulfilling substantial orders for existing international partners, and close pending deals that were contingent on the CE mark. We are excited that 2021 will be a great year of sales for the Company.”

The certification for the CE mark is valid until May 2024, and the Company’s updated quality management system will ensure prompt recertification.

About BioElectronics Corporation

BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Therapy for postoperative pain and chronic wound care.

Forward Looking Statements

Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Paul Knopick
9402623584
[email protected]

Alta Vista, an Atlas Company, Awarded a $5 Million Contract to Support the California Department of Transportation

AUSTIN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) — Atlas Technical Consultants, Inc. (Nasdaq: ATCX) (“Atlas” or the “Company”), a leading provider of professional testing, inspection, environmental, engineering, program management and consulting services, announced today that Alta Vista, an Atlas company, has been selected to perform professional and technical services to support the California Department of Transportation (“Caltrans”), Division of Construction, District 8. The 3-year contract is valued at approximately $5 million.

Caltrans’ District 8 is the largest of 12 statewide Districts and covers approximately 28,650 square miles of land. There are four interstates and 32 state routes totaling 7,200 lane miles within the District boundaries. Specific work within the agreement includes on-call materials field testing and plant inspections on Caltrans contracts in the counties of Riverside and San Bernardino, which include 49 incorporated cities.

L. Joe Boyer, Atlas’ Chief Executive Officer, said, “We are pleased to have recently added Alta Vista as part of the Atlas team. Alta Vista’s transportation expertise and wide range of services has already proved to be an exceptional contributor to the deep technical resources at Atlas.”

“This contract adds another win to our 12-year track record of providing Caltrans with our valuable materials engineering and testing services. With congestion relief being the state of California’s number one transportation priority, we are honored to have the privilege of assisting in this effort. We are extremely excited about this additional opportunity to build upon our strong relationship with Caltrans while further expanding our geographical reach into the Inland Empire,” said Alta Vista President Patrick Lowry.

Over the years, Alta Vista has become one of the leading providers of materials engineering and testing services for Caltrans, helping to deliver some of its largest public infrastructure projects. With contracts in almost every region of the State, they have used a disciplined approach to project management that capitalizes on their ISO-9001 certified quality management system to provide world class testing services on construction projects.

“Alta Vista puts its clients first in a very meaningful way. They really know how to move projects forward in a win-win fashion by cooperatively working with everyone involved. Their planning, execution, and ability to keep getting better is so unique in this industry,” said Daniel Speer, Retired Deputy Division Chief for Materials, Engineering, & Testing Services at Caltrans.


About Atlas Technical Consultants


Headquartered in Austin, Texas, Atlas is a leading provider of professional testing, inspection, engineering, environmental, program management and consulting services. Under the name Atlas Technical Consultants, we offer solutions to public and private sector clients in the transportation, commercial, water, government, education and industrial markets. With approximately 140 offices in 41 states and approximately 3,300 employees, Atlas provides a broad range of mission-critical technical services, helping clients test, inspect, certify, plan, design and manage a wide variety of projects across diverse end markets. For more information, go to https://www.oneatlas.com.


About Caltrans District 8


Caltrans District 8 covers Riverside and San Bernardino Counties in Southern California, which includes 49 incorporated cities. District 8 is the largest of 12 statewide Caltrans districts and covers approximately 28,650 square miles of land with 1400 employees and an operating budget of $144 million.


Contacts

Media Investors
Karlene Barron  512-851-1507
770-314-5270
[email protected]
[email protected]  

Akouos Reports Third Quarter 2020 Financial Results and Provides Business Highlights


– Expanded leadership team with appointment of Sachiyo Minegishi as CFO and promotion of Jennifer Wellman to COO –


– Continued progress towards 2021 IND submission for AK-OTOF, a gene therapy intended for the treatment of hearing loss due to mutations in the OTOF gene –


– Execution on build of internal manufacturing capabilities and infrastructure to support future research and clinical trials is on track –

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) — Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reported financial results for the third quarter ended September 30, 2020 and provided updated business highlights.

“We continue to advance AK-OTOF, a gene therapy intended for the treatment of hearing loss due to mutations in the OTOF (otoferlin) gene, towards a 2021 IND filing. Today, individuals with OTOF-mediated hearing loss have no therapeutic options. Our novel gene therapy candidate has the potential to restore hearing for these individuals, who typically have no functional hearing at birth,” said Manny Simons, Ph.D., founder, president and CEO of Akouos. “Also, despite the challenging environment around us, the team is executing on our plan to establish internal manufacturing capabilities and infrastructure to support IND-enabling studies and clinical trials. Our progress towards our long-term mission, making healthy hearing available to all, is a testament to our deeply committed, experienced team and our strategic partners.”



Business and Pipeline Highlights


  • Appointed Sachiyo Minegishi as chief financial officer –
    In October 2020, Sachiyo Minegishi joined Akouos as chief financial officer. Ms. Minegishi has 20 years of experience in the biotechnology and pharmaceutical industry, serving in various roles at global companies, as well as in investment banking, most recently leading the gene therapy program for sickle cell disease at bluebird bio.


  • Promoted Jennifer Wellman to chief operating officer –
    In October 2020, Akouos announced the promotion of Jennifer Wellman to chief operating officer, from her prior role as senior vice president of regulatory and quality. Ms. Wellman brings to Akouos over 20 years of experience in adeno-associated viral (AAV) vector gene therapy research and development, and was previously co-founder and head of product development strategy at Spark Therapeutics, Inc.


  • Continued progress towards IND filing in 2021 to enable a Phase 1/2 clinical trial for AK-OTOF, a gene therapy intended for the treatment of hearing loss due to mutations in the


    OTOF


    gene



    Through a targeted delivery of a proprietary ancestral AAV, known as AAVAnc80, containing the OTOF gene, Akouos aims to restore otoferlin expression, potentially restoring physiologic hearing and providing long-lasting benefits to individuals with OTOF-mediated hearing loss. Akouos plans to submit an IND application to the FDA in 2021 to conduct a Phase 1/2 clinical trial. The planned Phase 1/2 clinical trial consists of two parts. The first part is a dose escalation phase designed to assess the safety, tolerability and bioactivity of AK-OTOF, administered to trial participants through a single unilateral intracochlear injection. The second part is a cohort expansion phase designed to assess safety and efficacy.


  • Execution on build of internal manufacturing capabilities to support future research and clinical activities is on track



    Akouos is leveraging its expertise in gene therapy to develop internal, scalable manufacturing capabilities to support research, including IND-enabling studies, and current Good Manufacturing Practice activities for clinical trials. The plans to internalize manufacturing will enable more influence on the manufacturing process, associated analytics, and supporting quality systems, as well as increase the ability to control timelines, costs, and intellectual property.



Third Quarter 2020 Financial Results


  • Cash Position



    Cash, cash equivalents and marketable securities were $320.1 million as of September 30, 2020, as compared to $25.1 million as of December 31, 2019. Akouos expects the cash balance to fund operations for at least the next two years.

  • Research and Development (R&D) Expenses



    R&D expenses were $8.6 million for the third quarter ended September 30, 2020, compared to $4.4 million for the same period in 2019. The increase was primarily due to the increased efforts in preclinical IND-enabling studies for AK-OTOF and the growth in the number of R&D employees and their related activities, as well as the expense allocated to R&D related to Akouos’s leased facilities.

  • General and Administrative (G&A) Expenses



    G&A expenses were $4.5 million for the third quarter ended September 30, 2020, compared to $0.9 million for the same period in 2019. The increase was primarily due to the growth in the number of G&A employees and other administrative expenses, as well as the expense allocated to G&A related to Akouos’s leased facilities.

  • Net Loss



    Net loss was $13.1 million, or $0.85 loss per share, for the third quarter ended September 30, 2020, compared to $8.2 million, or $13.21 loss per share, for the same period in 2019.



About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.


Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation, plans, and timing of our future clinical trials and our research and development programs, our expectations regarding our manufacturing capabilities, and the period over which we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: our plans to develop and, if approved, subsequently commercialize our product candidates; the timing of and our ability to submit applications for, and obtain and maintain regulatory approvals for, our product candidates; our expectations regarding our regulatory strategy; our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents and marketable securities; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential addressable patient population for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates; our intellectual property position; our ability to identify additional products, product candidates, or technologies with significant commercial potential that are consistent with our commercial objectives; the impact of government laws and regulations; our competitive position and expectations regarding developments and projections relating to our competitors and any competing therapies that are or become available; developments and expectations regarding developments and projections relating to our competitors and our industry; the impact of the COVID-19 pandemic on our business, results of operations, and financial condition; our ability to maintain and establish collaborations or obtain additional funding; and other factors discussed in the “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2020 filed with the Securities and Exchange Commission, and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.


Condensed Consolidated Balance Sheet Data



 (Unaudited)


(in thousands)

               
   
September 30, 2020
 
December 31, 2019
   
 
     
Cash, cash equivalents and marketable securities   $ 320,074     $ 25,078  
Total assets     342,247       45,162  
Total liabilities     20,939       19,273  
Convertible preferred stock           58,690  
Total stockholders’ equity (deficit)     321,308       (32,801 )
                 






Condensed Consolidated Statements of Operations and Comprehensive Loss



(Unaudited)


(in thousands, except share and per share data)

                         
   
Three Months Ended
 
Nine Months Ended
   
September 30, 
 
September 30, 
   
2020
   
2019
   
2020
   
2019
 
   
 
 
 
 
 
 
 
Operating expenses:                        
Research and development   $ 8,641     $ 4,377     $ 26,612     $ 11,886  
General and administrative     4,478       887       9,646       2,267  
Total operating expenses     13,119       5,264       36,258       14,153  
Loss from operations     (13,119 )     (5,264 )     (36,258 )     (14,153 )
Other income (expense):                        
Change in fair value of preferred stock tranche liability           (3,013 )           (2,260 )
Interest income     21       70       201       298  
Other income (expense), net     9       (3 )     5       (8 )
Total other income (expense), net     30       (2,946 )     206       (1,970 )
Net loss   $ (13,089 )   $ (8,210 )   $ (36,052 )   $ (16,123 )
Net loss per share attributable to common stockholders, basic and diluted   $ (0.85 )   $ (13.21 )   $ (3.01 )   $ (27.48 )
Weighted‑average common shares outstanding, basic and diluted     15,334,241       621,581       11,991,870       586,728  
Other comprehensive income:                        
Unrealized gain on marketable securities     8             8        
Total other comprehensive income     8             8        
Total comprehensive loss   $ (13,081 )   $ (8,210 )   $ (36,044 )   $ (16,123 )
                         









Contacts


Media:

Katie Engleman, 1AB
[email protected]

Investors:

Courtney Turiano, Stern Investor Relations
[email protected]

iTeos Appoints Matthew Roden, Ph.D. to Board of Directors

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced the appointment of Matthew Roden, Ph.D., to its Board of Directors. Dr. Roden joins the Board as a Partner of MPM Capital and will replace Ansbert Gadicke, M.D.

“Matt will be a tremendous addition to our board due to his vast leadership experience spanning both the pharmaceutical and financial industries,” said David Hallal, chairman of the iTeos Board of Directors. “He will offer a holistic corporate development perspective and strategic support that will allow us to continue our evolution as both a clinical-stage, and newly public, company. In particular, his deep experience in global transactions will add dimension to our board and complement the innovation and scientific rigor displayed by our leadership team to date.”

“Ansbert played a key role in building iTeos from its early development through its clinical and corporate growth. On behalf of the members of the management team and my fellow board members, I would like to thank him for his significant contributions to our success,” said Michel Detheux, Ph.D., Co-Founder, President and Chief Executive Officer of iTeos. “I look forward to working together with Matt to continue delivering on our common mission to develop life-transforming cancer therapies to patients in need.”

“I am excited to join the iTeos board,” said Dr. Roden “I have been very impressed with iTeos’ progress and position it has established as a leader in both identifying and developing next-generation immuno-oncology targets. The leadership team’s expertise in tumor immunology has put iTeos at the forefront of the next wave of potential best-in-class cancer therapies, and I look forward to working together to advance its mission.”

Dr. Roden is an Executive Partner at MPM Capital. Prior to joining MPM Capital, he was Senior Vice President and Head of Enterprise Strategy at Bristol Myers Squibb. Earlier, he served as Head of Strategic Corporate Development and Head of Global BD Assessment, leading teams on over 100 business development transactions that are cumulatively valued at over $125 billion. Before joining Bristol Myers Squibb, Dr. Roden led equity research on the biotechnology sector at UBS Investment Bank. Earlier, he was a Senior Equity Analyst covering biotechnology at J.P. Morgan, and Bank of America Merrill Lynch, and was an Associate at Credit Suisse First Boston. Dr. Roden earned his Ph.D. at the Albert Einstein College of Medicine, focusing on the structural biology of immune-relevant molecules, and earlier was a pre-doctoral clinical research fellow in immuno-oncology at the National Cancer Institute in Bethesda, Maryland. Dr. Roden holds a M.S. degree from Georgetown University and a B.S. from George Mason University.

About iTeos Therapeutics, Inc.

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2AR, in the adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is being investigated in an open-label multi-arm Phase 1/2a clinical trial in adult cancer patients with advanced solid tumors and encouraging preliminary single-agent activity was observed in the dose escalation portion of the trial. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, a checkpoint with multiple mechanisms leading to immunosuppression. EOS-448 was also selected to engage FcγR, to promote ADCC activity. An open-label Phase 1/2a clinical trial of EOS-448 was initiated in adult cancer patients with advanced solid tumors. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.

For further information, please contact:

Media Contact
s
:

Amber Fennell, Paul Kidwell
Consilium Strategic Communications
+44 203 709 5700
[email protected]

Investor Contact
s
:

Sarah McCabe, Zofia Mita
Stern Investor Relations, Inc.
+ 1 212 362 1200
[email protected]

Wedge and ApplicantPro Help Automate Candidate Screening

Integration Between HR Technology Providers Saves Recruiting Teams Hours Every Week

HOLLAND, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) — Wedge, the video screening solution that helps recruiters make authentic connections with candidates, today shared details about its ongoing partnership with the applicant tracking system and hiring software provider, ApplicantPro.

“ApplicantPro is known for delivering hiring solutions customized to meet the needs of individual organizations. Wedge helps further that mission, making it possible to automate and streamline the screening process, from anywhere, at any time,” said Matt Baxter, CEO of Wedge. “Through this integration, ApplicantPro customers are saving more than five hours a week with Wedge, at a time when resources are limited, and applicant volumes are way up.”

Ryan Kohler, founder and CEO of ApplicantPro, commented, “At ApplicantPro, we aim to help companies, managers and HR teams improve their hiring results. In addition to our software, we partner with like-minded companies to ensure our customers have what they need to make that happen. Wedge is just that, a forward-thinking solution able to enhance screening speed and quality to support better hires.”

With this integration, ApplicantPro customers can connect Wedge to their ATS in minutes, gaining the ability to add one-way video screens to their recruiting process. Recruiting teams can access more candidates in less time by asking job seekers to complete a “Wedge” from their web browser at their convenience. There is no additional app required to download, and candidates can record responses on any device. This asynchronous approach can reduce screening time by 75 percent while enabling recruiters to get to know candidates beyond their resumes.

To learn more about the Wedge and ApplicantPro integration, visit https://www.wedgehr.com/applicant-pro.

About Wedge

Founded in 2015 by serial entrepreneur Matt Baxter, Wedge is the one-way recorded video interview that enables candidates to show their true selves. For more information, visit wedgehr.com.

About
ApplicantP
ro

Over the past 15 years, ApplicantPro has been optimizing the hiring process for over 7,000 organizations and counting — becoming a leading provider of easy-to-use hiring software to source, screen, and maintain qualified applicants. For more information, visit applicantpro.com

Note to editors: Trademarks and registered trademarks referenced herein remain the property of their respective owners.

Media Contact for Wedge:
Kate Achille
The Devon Group
[email protected]

Oyster Consulting Expands Midwest Presence

Industry Veterans Anderson, Roth and Wegener Bolster Consulting Firm

RICHMOND, Va., Nov. 12, 2020 (GLOBE NEWSWIRE) — Oyster Consulting, a financial services consulting firm providing consulting, outsourcing and software services, announced today that Steve Anderson has joined the firm, adding depth to its mid-west presence. Steve joins other recent mid-western hires Jim Roth and Ed Wegener, as well as Mary Jane Phillips, who joined the firm in 2018.

With over 25 years in the financial services industry, Steve’s leadership experience within insurance companies and independent broker-dealers provides depth in these markets. His drive to improve firms’ profitability and customer service is a great addition to Oyster Consulting’s expanding Strategic Planning & Execution team. His experience with mergers and acquisitions, clearing firms and self-clearing platforms, recruiting, and insurance sales and operations allow him to provide Oyster’s clients with a well-rounded perspective. 

Prior to joining Oyster, Steve served as the CEO of Waterstone Financial Group, a provider of back office support to over 750 financial advisors and had more than 50 home office employees with over $13b of client assets under management. Upon LPL Financial Group’s acquisition of Waterstone, Steve was named Executive Vice President for LPL Financial and served as a member of the Executive Management Team.
  
“Having Steve on the team is a tremendous uptick in our expansion. His relationships are at the executive level, bolstering our Strategic Planning, Match, and Placement product areas. We are very proud and excited to have Steve on the team,” said Pete Bowman, Managing Director or Oyster’s Strategic Planning and Execution team.  

“I am excited to be joining the professionals at Oyster Consulting as they continue to grow their Strategic Planning and Execution practice, including Mergers and Acquisitions and Insurance Product consulting.  I am looking forward to working with my existing relationships and developing new opportunities, particularly in the Midwest Region,” said Anderson.  

ABOUT OYSTER CONSULTING


Oyster Consulting
provides consulting, outsourcing and software solutions to the financial services industry. Our experienced industry practitioners add more value than career consultants and help us approach each client with unbiased information and practical solutions to meet their challenges.

CONTACT
Pete Bowman
Managing Director, Strategic Planning & Execution Team, Oyster Consulting LLC
(804) 965-5400
[email protected] 
www.oysterllc.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0b38ea48-1d08-4921-953c-ab9ef7666ae4

 

CI Financial Reports Financial Results for the Third Quarter of 2020

CI Financial Reports Financial Results for the Third Quarter of 2020

  • Earnings per share of $0.62 for the quarter
  • Comparable selling, general and administrative expenses (SG&A) down $19.4 million and total SG&A down $15.8 million from Q3-2019
  • Repurchased 4.3 million shares for $77.7 million and paid $38.6 million in dividends ($0.18 per share)
  • At quarter-end, wealth management assets reach new record of $66.1 billion with the acquisitions of Balasa Dinverno Foltz and Congress Wealth Management
  • After quarter-end, following the acquisition of Canadian advisory firm Aligned Capital and other announced transactions, wealth management assets will grow to a record $83 billion and total assets to a record $209 billion
  • CI common shares to trade on NYSE under “CIXX” starting November 17, 2020
  • Corporate rebrand creating consistency across CI’s businesses

TORONTO–(BUSINESS WIRE)–CI Financial Corp. (“CI”) (TSX: CIX) today released unaudited financial results for the quarter ended September 30, 2020.

“Our financial results were strong for the quarter with earnings per share of $0.62 and free cash flow of $144 million – an increase of 12% from last quarter,” said Kurt MacAlpine, CI Chief Executive Officer. “These results are due in part to our continued cost discipline. We have successfully cut SG&A expenses by $16 million year over year even as we have made several acquisitions this year. Excluding the impact of acquisitions, we reduced expenses by $19 million over the third quarter of last year.”

“We also made incredible progress this quarter executing against our three strategic priorities of modernizing asset management, expanding wealth management, and globalizing the firm,” Mr. MacAlpine said.

“During the third quarter, we closed on the acquisition of two U.S. wealth management firms and have subsequently reached agreements to purchase another four high-quality firms in strategic locations across the United States. These transactions will boost our U.S. wealth assets to about $22 billion, giving us a significant presence in the United States in less than a year.

“With the acquisition in October of Aligned Capital Partners of Burlington, Ontario, we have achieved exceptional scale in our wealth management business, with assets of $61 billion in Canada and total North American wealth assets of about $83 billion,” Mr. MacAlpine said.

“Consistent with our globalization strategy, we are listing our common shares on the New York Stock Exchange starting next week, which should broaden CI’s investor base and increase its corporate profile.

“We have also started rolling out the new corporate branding for CI and our subsidiaries, including the introduction of CI Global Asset Management, CI Assante Wealth Management, CI Direct Investing and CI Investment Services, as well as launching a new CI Financial website,” Mr. MacAlpine said. “The modernized brands provide consistency across the CI Financial group and reduce the complexity of our service and product offerings – making it easier for advisors and investors to do business with CI.”

Financial Results

CI reported earnings per share of $0.62 for the third quarter of 2020, compared to $0.56 in the previous quarter and $0.60 in the third quarter of 2019.

SG&A expenses for the third quarter were $108.8 million, down slightly from $109.0 million in the second quarter and down $15.8 million or 13% from $124.6 million in the third quarter of 2019. Excluding the additional expenses of firms acquired by CI this year, SG&A expenses were $105.2 million for the quarter, representing a decline of $19.4 million or 16% from the third quarter a year ago. For the first nine months of 2020, SG&A expenses excluding acquisitions were down by $49.1 million or 13% compared to the same period of 2019.

CI generated $143.9 million in free cash flow1 during the third quarter, an increase of 12% from $128.3 million in the second quarter and a decline of 1% from 144.7 million in the same quarter a year ago.

At September 30, 2020, total ending assets under management were $128.3 billion, an increase of 2% from June 30, 2020 and a decline of 1% from September 30, 2019. Core assets under management, which consists of assets managed by CI’s Canadian and Australian subsidiaries, were $123.6 billion at September 30, 2020, an increase of 2% from three months earlier and a decline of 5% year over year. During the third quarter, U.S. assets under management grew by 10% to $4.7 billion.

Total average assets under management were $129.0 billion for the third quarter, up 7% from $120.1 billion for the second quarter and down slightly from $129.4 billion in the third quarter of 2019. Core average assets under management were $124.6 billion in the third quarter, compared to $118.4 billion for the previous quarter and $129.4 billion for the year-ago quarter.

Total wealth management assets as at September 30, 2020 were $66.1 billion, which represents a quarter-end record for CI and an increase of $12.3 billion or 23% over June 30, 2020 and an increase of $18.0 billion or 37% year over year.

Canadian wealth management assets, at $51.2 billion, increased 4% during the quarter and 6% from one year ago. This includes the assets of Assante Wealth Management (Canada) Limited, CI Private Counsel LP, CI Direct Investing (WealthBar Financial Services Inc.) and Virtual Brokers.

U.S. wealth management assets were $14.9 billion at September 30, 2020, up $10.0 billion over the quarter. During the quarter, CI acquired Balasa Dinverno Foltz LLC and an interest in Congress Wealth Management, LLC. U.S. wealth management also includes assets of The Cabana Group, LLC, One Capital Management, LLC and Surevest, LLC.

CI reported $2.0 billion in overall net redemptions for the third quarter of 2020. CI’s Canadian retail business, excluding products closed to new investors, had $1.4 billion in net redemptions, relatively unchanged versus the third quarter of 2019. CI’s Canadian institutional business had net redemptions of $1.1 billion, an increase of $0.7 billion from the same quarter a year ago. Consistent with CI’s previous quarter, nearly all the institutional redemptions came from bank and insurance-owned asset managers with in-house internal investment teams. GSFM had $0.4 billion of net sales for the third quarter of 2020, and CI’s U.S. RIA business had $0.3 billion in net sales. CI’s closed business, comprised primarily of segregated fund contracts that are no longer available for sale, had $0.2 billion in net redemptions for the quarter.

Capital Allocation

In the third quarter of 2020, CI repurchased 4.3 million shares at a cost of $77.7 million and paid $38.6 million in dividends ($0.18 per share). For the month of October 2020, CI repurchased a further 0.9 million shares, ending the month with 210,548,302 shares outstanding.

The Board of Directors declared a quarterly dividend of $0.18 per share, payable on April 15, 2021, to shareholders of record on March 31, 2021. The annual dividend rate of $0.72 per share represented a yield of 4.4% on CI’s closing share price of $16.32 on November 11, 2020.

New York Stock Exchange listing – “CIXX”

CI also announced today that its common shares have been approved for listing on the New York Stock Exchange (the “NYSE”). CI expects its common shares will commence trading on the NYSE as of market open on November 17, 2020 under the ticker symbol “CIXX.” This move is expected to broaden CI’s investor base, increase its corporate profile in the U.S. and allow CI to offer U.S. dollar-denominated shares as consideration when making acquisitions in the U.S.

In addition to listing and trading on the NYSE in U.S. dollars, CI’s common shares continue to be listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol “CIX.” Shareholders who purchased their CI common shares on the TSX and, in connection with the NYSE listing, wish to trade in U.S. dollars are advised to contact their broker for more information.

Shareholders who purchased their CI common shares “over-the-counter” or OTC, including shareholders whose shares are denoted in their institution/broker account with the symbol “CIFAF”, are advised to monitor their account to ensure their holdings are updated to reflect the NYSE listing and trading symbol, as the Company expects OTC quotations for CI common shares to cease in connection with the NYSE listing. Shareholders are advised to contact their broker for more information if they have questions in this regard.

Business highlights

  • CI made significant progress in expanding its U.S. wealth management business. During the quarter:

    • CI acquired 100% ownership of Balasa Dinverno Foltz of Itasca, Illinois, a leading Chicago-area RIA with approximately $6.2 billion in assets.
    • CI announced in September an agreement to purchase 100% of Bowling Portfolio Management LLC of Cincinnati, Ohio, an RIA with $590 million in assets.
    • OCM Capital Partners LLC, which is majority owned by CI and is the parent company of One Capital Management, LLC of Westlake Village, California, announced an agreement to purchase Thousand Oaks Financial Holding, LLC, an RIA based in Thousand Oaks, California operating under the name Professional Planning. The acquisition closed in October and Thousand Oaks is being integrated into One Capital.
    • CI completed in July the acquisition of a strategic interest in Congress Wealth Management, LLC of Boston, a firm with approximately $3.6 billion in assets.
  • CI acquired a majority interest in Aligned Capital Partners Inc. of Burlington, Ontario, a full-service investment dealer with approximately $11 billion in assets and more than 200 financial advisors across Canada. The acquisition was announced in August and closed on October 19, 2020.
  • CI initiated its plan to rebrand the company and its subsidiaries. The changes will streamline CI’s lineup of brands, unify its operations under the CI name, and give the company a modern image reflecting its position as an integrated global asset and wealth management company. During the quarter, WealthBar Financial Services rebranded as CI Direct Investing. Following quarter-end, Assante was rebranded to CI Assante Wealth Management, CI Investments Inc. rebranded as CI Global Asset Management, BBS Securities Inc. was renamed CI Investment Services Inc., and CI Financial launched a new website to reflect the updated branding.
  • The Cabana Group subsidiary, Cabana Asset Management, launched a US$1 billion lineup of exchange-traded funds using Cabana’s innovative and proven target drawdown investment strategy. The Target Drawdown ETFs were listed on the New York Stock Exchange in September and build on the proven track record of Cabana’s Target Drawdown Professional Series of separately managed accounts, which have been available in the U.S. since 2012.

Following quarter-end:

  • CI announced three RIA transactions, agreeing to acquire:

    • 100% of The Roosevelt Investment Group, Inc., a New York-based wealth manager with approximately $3.6 billion in assets.
    • Full ownership of Doyle Wealth Management, Inc. of St. Petersburg, Florida, which has approximately $1.5 billion in assets.
    • A majority interest in Stavis & Cohen Financial LLC of Houston, a firm with approximately $759 million in assets.

Analysts’ conference call (updated)

CI will hold a conference call with analysts today at 10:00 a.m. Eastern Time, led by Chief Executive Officer Kurt MacAlpine and Chief Financial Officer Douglas Jamieson. The call and a slide presentation will be accessible through a webcast, which can also be reached through the Events section of the Investor Relations page on www.cifinancial.com. Alternatively, investors may listen to the discussion by dialing 1-800-367-2403 or 647-490-5367 (Passcode: 7837577). A replay of the call will be available for one year following the presentation (Passcode: 7837577). The webcast will be archived in the Financials section of www.cifinancial.com.

Financial highlights

 

As at and for the quarters ended

Change (%)

[C$ millions, except share amounts]

Sept. 30, 2020

June 30, 2020

Sept. 30, 2019

QoQ

YoY

Core assets under management

123,605

121,286

129,615

2

(5)

U.S. assets under management

4,707

4,277

10

n/a

Total assets under management

128,312

125,563

129,615

2

(1)

Canadian wealth management

51,189

49,003

48,099

4

6

U.S. wealth management

14,937

4,872

207

n/a

Total wealth management assets

66,127

53,875

48,099

23

37

Total assets

194,438

179,438

177,714

8

9

Core average assets under management

124,626

118,413

129,426

5

(4)

Total average assets under management

129,021

120,104

129,426

7

 

 

 

 

 

 

Net income attributable to shareholders

130.6

120.2

139.0

9

(6)

Adjusted net income1

130.6

120.2

139.0

9

(6)

Basic earnings per share

0.62

0.56

0.60

11

3

Diluted earnings per share

0.61

0.55

0.60

11

2

Adjusted earnings per share1

0.62

0.56

0.60

11

3

 

 

 

 

 

 

Free cash flow1

143.9

128.3

144.7

12

(1)

Return on equity2

34.9%

35.4%

37.6%

 

 

Dividends paid per share

0.18

0.18

0.18

Dividend yield

4.3%

4.2%

3.7%

 

 

 

 

 

 

 

 

Average shares outstanding

211,347,613

216,202,545

232,140,211

(2)

(9)

Share price – High

19.68

18.46

21.97

7

(10)

Share price – Low

16.80

10.53

18.00

60

(7)

Share price – Close

16.89

17.27

19.33

(2)

(13)

Change in share price

(2.2%)

23.6%

(9.4%)

 

 

Total shareholder return

(1.2%)

24.9%

(8.6%)

 

 

Market capitalization

3,542

3,694

4,410

(4)

(20)

P/E ratio2

7.0

7.2

8.3

(3)

(16)

 

 

 

 

 

 

Long term debt (including current portion)

1,962

1,988

1,569

(1)

25

Net debt1

1,669

1,374

1,341

21

24

Net debt to adjusted EBITDA1

2.05

1.83

1.62

12

27

1Free cash flow, net debt, adjusted net income, adjusted earnings per share and adjusted EBITDA are not standardized earnings measures prescribed by IFRS. Descriptions of these measures, as well as others, and reconciliations to the nearest IFRS measures, where necessary, are included in Management’s Discussion and Analysis available at www.cifinancial.com.

2Trailing 12 months, calculated using adjusted net income

For detailed financial statements for the quarter ended September 30, 2020, including Management’s Discussion and Analysis, which contains discussions of non-IFRS measures, please see CI’s website at www.cifinancial.com under Investor Relations / Financials, or contact [email protected].

About CI Financial

CI Financial Corp. (TSX: CIX) is an independent company offering global asset management and wealth management advisory services. CI’s primary asset management businesses are CI Global Asset Management and GSFM Pty Ltd., and it operates in wealth management through Assante Wealth Management (Canada) Ltd., CI Private Counsel LP, Aligned Capital Partners Inc., CI Direct Investing (WealthBar Financial Services Inc.), CI Investment Services Inc., Balasa Dinverno Foltz LLC, The Cabana Group, LLC, Congress Wealth Management, LLC, One Capital Management, LLC and Surevest LLC. Further information is available at www.cifinancial.com.

All financial amounts in Canadian dollars unless stated otherwise.

CI Global Asset Management is a registered business name of CI Investments Inc.

This press release contains forward-looking statements concerning anticipated future events, results, circumstances, performance or expectations with respect to CI Financial Corp. (“CI”) and its products and services, including its business operations, strategy and financial performance and condition. Forward-looking statements are typically identified by words such as “believe”, “expect”, “foresee”, “forecast”, “anticipate”, “intend”, “estimate”, “goal”, “plan” and “project” and similar references to future periods, or conditional verbs such as “will”, “may”, “should”, “could” or “would”. Forward-looking statements in this press release include statements about the potential listing of CI’s common shares on the NYSE, the timing and satisfaction of any conditions relating thereto, the potential impact thereof on CI’s investor base, corporate profile and acquisition strategy and “over-the-counter” quotations. These statements and other forward-looking statements are not historical facts but instead represent management beliefs regarding future events, many of which by their nature are inherently uncertain and beyond management’s control. Although management believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements involve risks and uncertainties. The material factors and assumptions applied in reaching the conclusions contained in these forward-looking statements include that the investment fund industry will remain stable and that interest rates will remain relatively stable. Factors that could cause actual results to differ materially from expectations include, among other things, general economic and market conditions, including interest and foreign exchange rates, global financial markets, changes in government regulations or in tax laws, industry competition, technological developments and other factors described or discussed in CI’s disclosure materials filed with applicable securities regulatory authorities from time to time. The foregoing list is not exhaustive and the reader is cautioned to consider these and other factors carefully and not to place undue reliance on forward-looking statements. Other than as specifically required by applicable law, CI undertakes no obligation to update or alter any forward-looking statement after the date on which it is made, whether to reflect new information, future events or otherwise.

Investor Relations

Jason Weyeneth, CFA

Vice-President, Investor Relations & Strategy

(416) 681-8779

[email protected]

Media

Murray Oxby

Vice-President, Communications

(416) 681-3254

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo
Logo

Osino Resources Expands Twin Hills Central Strike Length to 1500M and Discovers New High-Grade Shoots, Phase 2 Drilling Progressing Well

  •  
    118 holes
    (
    25,000m
    )
    drilled
    at THC
    since August 2
    020; 155
    holes (33,300m) drilled to date

  • Highlights from the latest results include:

    • 327m @ 0.76g/t (OKD058: 22 – 349m),
      incl.
      94
      m @ 1.
      35
      g/t
    • 332
      m
      @
      0.
      82
      g/t (
      OKD0
      22
      :
      67

      399
      m),
      incl.
      57
      m @
      2.08
      g/t
    • 149
      m @
      1.12
      g/t
      (
      OK
      R
      0
      32
      :
      40 – 189
      m)
      ,
      incl.
      60
      m @ 1.
      70
      g/t
    • 150m @ 0
      .
      89
      g/t (OK
      R037
      :
      13

      163
      m)
      ,
      incl.
      15m @ 2.32g/t
    • 2
      31
      m @ 0.6
      4g/t (OKD074
      :
      16

      247
      m),
      incl.
      2
      0
      m @ 1.
      5
      0g/t
      and 46m @ 1.00g/t
    •    99m @ 0.87g/t (OKR080: 121 – 220m), incl. 8m @ 3.67g/t and 3m @ 5.15g/t
    •    41m @ 1.52g/t (OKR057: 37 – 78m)
  • Significant increase in mineralized strike to 1,500m
    with depths up to
    350m
    and widths
    up to 250m
  • Two n
    ew
    zone
    s
    of
    high

    grade mineralization
    and
    down

    dip continuity
    proven to 350m
    depth
  • Phase 2
    drilling
    re-
    commenced with 8 drill rigs
    ,
    compris
    ing ~
    67 holes for
    20
    ,000m
    to be completed by January 2021

VANCOUVER, British Columbia, Nov. 12, 2020 (GLOBE NEWSWIRE) — Osino Resources Corp. (TSXV: OSI) (FSE: RSR1) (OTCQB:OSIIF) (“Osino” or “the Company”), is pleased to provide an update on the resource drilling and exploration of Osino’s Twin Hills Central (“THC”) gold project in north-central Namibia, where the Company holds a dominant 7,000 km2 land position. THC is part of the large, sedimentary-hosted and structurally controlled Twin Hills gold system which was discovered by Osino in 2019.

Heye Daun, Osino’s President & CEO commented: The results of this year’s drilling have far exceeded our expectationsand have further strengthened our conviction in Twin Hills Central’sgrowing stature as Namibia’s next major gold deposit. The closely spaced drilling (50x50m collars) demonstrates excellent continuity of mineralization along strike, down dip and towards the north-east where we have discovered an unexpected but welcome, shallower zone of mineralization. Hole OKR080 on the north side is particularly exciting as it intercepted high grade in a new shoot (8m @ 3.67g/t) and ended in another highgrade intercept of 3m @ 5.46g/t. There have also been several mineralized holes in the gap between the western and eastern lobes (including two with shallow higher grade) in an area previously thought to be barren. We are accordingly putting in place the manpower and infrastructure to be able to expand our drilling rate next year beyond the currently used 8 rigs. This will enable us to fast-track the development drilling whilst at the same time expanding brownfields exploration and target testing to make new discoveries.”

Twin Hills Central Resource Drilling

In-fill and step out drilling to define a Maiden Resource Estimate (“MRE”) is underway at THC with five diamond and three RC drill rigs. The first phase of the MRE drilling (33,300m) was completed on October 11th and after a short break the second phase (20,000m) commenced on October 27th, to be completed by February 2021.   As much as possible, but likely not all, of that drilling will be included in the 43.101 compliant resource estimate which Osino plans to publish before the end of Q1 2021.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c6011a60-d32e-4164-b4de-925ffa57d20b

Drilling is being carried out on 50 x 50m drill spacing, covering the entire THC deposit, with drill depths of mostly 200m at 60 degrees inclination towards the south. Two deep holes (OKD058 and OKD022) were drilled towards the NNW (opposite to all the other holes) to test the continuity and down-dip extent of the mineralization and to see if there are other mineralizing structures not picked up in the rest of the holes.

Drilling on the western lobe of THC has defined a very wide, consistently mineralized zone vertically down to 350m and open to depth. Recent drilling indicates that the mineralization continues in a narrower zone along strike to the southwest.

The eastern lobe of THC has grown significantly since the previous news release, dated August 24, 2020. A new zone of high-grade gold to the north of the previously known mineralization was discovered with hole OKR080 (8m @ 3.67g/t). In addition, the eastern lobe has been expanded on strike by about 150m to the east along the strong IP anomaly and west into the gap between the western and eastern lobes, which was previously thought to be barren.

The gap between the east and West Lobes has been greatly diminished with the discovery of shallow high-grade mineralization in hole OKR056 (25m @ 2.00g/t) as well as the expansion of the East Lobe.

West Lobe

Assays received for the West Lobe (or what is sometimes referred to as the “bulge”) have confirmed and extended the unusual width and continuity of mineralization, which is exceptionally wide for an orogenic style deposit. It now has a maximum apparent width of 250m and is continuous down dip to beyond 300m (refer to Figure 2).

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5c6b2eb1-84c8-4b75-a215-4416a818da02

The West Lobe also has a higher-grade core, which plunges towards the northeast and deeper holes confirm that this mineralization keeps going to depth in the northeasterly direction. In addition, recent drilling on the south western edge of this lobe indicates that a narrow zone of gold mineralization continues in this direction as well (refer to Figure 1). Phase 2 drilling will include further deep drilling to test the mineralization at depth and along strike to the west and northwest.

East Lobe

The East Lobe has mineralization up to 100m wide and 300m down dip, potentially going deeper as indicated on Figure 3 below. The grades in the East Lobe are generally higher than in the West Lobe and appear to be focused into narrower zones, although the style of mineralization and host rocks are the same.

The size of the East Lobe has increased substantially and has extended the strike extent of THC by 150m to the east and remains open along strike and depth. Recent drilling indicates that the mineralization continues to the east of the previously reported margin, along a strong IP anomaly which is visible in Figure 1.

Hole OKR080, which is the most northerly hole drilled on the East Lobe to date, intersected a previously unknown zone of high-grade mineralization (8m @ 3.67g/t) and also ended in high grade at 220m (3m @ 5.15g/t). Refer to Figure 4 above.

Additional drill holes have now been added to the north and east of the East Lobe for the Phase 2 drilling to be completed before February 2020.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/efd7ef82-1752-402a-b66d-0699757fae6e

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2730cee0-f168-406d-900e-90ab8bf931e0

The Gap

The area between the West and East Lobes has had significant additional drilling since the previous news release dated August 24, 2020, and a number of mineralized intercepts have been returned including 25m @ 2.00g/t (OKR056) and 96m @ 0.74 incl. 18m @ 1.31g/t (OKR064).

The results to date indicate that the mineralization continues between the West and East lobes as a series of wider spaced zones. This augurs well for the development of a continuous large-scale pit over the entire THC strike length.

Drill Plan and Table of Significant Intercepts

Figure 5 below is a plan of all holes drilled and planned for the THC maiden resource estimate. The collars in blue with black center are completed holes that have assays outstanding. The holes planned for Phase 2 of the MRE drill program are shown as black squares.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7daa4301-8467-435b-a47c-d6fc9f5bca48

Figure
5
: Plan of THC MRE drill program. Solid colors – assays received. Blue with black center – assays awaited. Black square – planned for Phase 2 November
2020

January
202
1
.

The table on the following pages summarizes the significant intercepts received since the previous news release of drill assays from THC.

Table 1: Significant Intercept
s
for
Drill Holes received since previous
n
ews
r
elease (August
24
)

Hole From To Width Grade X Y
DIAMOND DRILL HOLES
OKD022*1 67 399 332 0.82 601076 7584724
incl.     12 1.66    
and     9 1.69    
and     57 2.08    
and     5 1.16    
and     25 2.12    
OKD0521 6 23 17 0.85 601074 7584723
incl.     3 2.49    
OKD0551 166 246 80 0.85 601010 7584906
incl. 25 53 25 1.70    
OKD058*
1
22 349 327 0.76 600137 7584341
incl.     94 1.35    
and     23 1.22    
OKD0641 25 58 33 0.50 601173 7584750
incl.     5 1.57    
OKD066 No significant intercepts 599959 7584534
OKD067 No significant intercepts 601263 7584785
OKD0681 152 257 105 0.70 600943 7584933
incl.     38 1.33    
OKD0701 159 201 42 0.84 601211 7584927
incl.     12 1.13    
and     7 1.21    
and     7 1.44    
OKD0721 118 159 41 0.76 601074 7584878
incl.     14 1.08    
OKD0741 16 247 231 0.64 600043 7584464
incl.     20 1.50    
and     46 1.00    
OKD0751 205 241 36 0.53 600470 7584742
incl.     10 1.01    
OKD0761 29 34 5 0.53 600321 7584577
incl. 38 42 4 0.51    
and 50 57 7 0.69    
and 67 75 8 0.45    
and 82 86 4 0.62    
and 100 123 23 0.65    
and 128 136 8 0.80    
and 161 165 4 0.83    
and 181 187 6 0.60    
and 201 204 3 1.04    
and 252 267 15 0.84    
OKD0771 120 317 197 0.51 600025 7584508
incl.     6 1.18    
and     4 1.21    
and     2 1.63    
and     13 1.53    
and     21 1.09    
OKD0791 78 252 174 0.56 600132 7584499
incl.     58 0.93    
and     18 1.56    
OKD0801 200 233 33 0.96 601105 7584941
incl.     7 2.11    
OKD0811 138 303 165 0.76 600117 7584547
incl.     8 1.13    
and     9 1.17    
and     12 1.44    
and     22 1.56    
OKD0831 183 348 165 0.67 600191 7584633
incl.     27 1.10    
OKD0841 170 204 34 0.77 600598 7584842
OKD0851 246 275 29 1.00 601089 7584987
OKD086 No significant intercepts 601703 7585011
OKD0871 96 139 43 0.63 600376 7584704
incl.     8 1.09    
OKD0881 116 131 15 1.15 600576 7584761
incl. 191 197 6 1.59    
OKD0891 125 131 6 1.03 601152 7584957
incl. 207 224 17 0.52    
and 255 260 5 1.89    
OKD0951 165 167 2 0.84 601196 7584976
and 181 184 3 0.60    
and 232 261 29 0.48    
OKD1001 24 255 231 0.65 600224 7584539
incl.     21 1.12    
and     26 0.95    
and     24 0.93    
and     7 1.23    
and     6 1.03    
        
RC DRILL HOLES
OKR0221 70 79 9 1.15 601106 7584782
OKR0231 43 126 83 0.66 601045 7584813
Incl.     16 1.37    
and     4 1.59    
and     7 1.71    
OKR024 No significant intercept 599962 7584378
OKR0251 79 109 30 0.51 601090 7584831
OKR0261 44 67 23 0.69 599983 7584333
and 93 103 10 0.60    
OKR0271 24 106 82 0.61 600072 7584369
incl.     20 1.35    
and     7 1.07    
OKR0281 80 87 7 0.82 601137 7584844
incl. 101 105 4 1.11    
OKR0291 38 177 139 0.80 600056 7584413
incl.     40 1.04    
and     23 1.45    
and     7 1.75    
OKR0301 8 27 19 0.67 601125 7584738
incl.     3 1.40    
and     3 1.05    
OKR031 11 15 4 1.34 601024 7584695
OKR032
1
40 189 149 1.12 600147 7584456
incl.     60 1.70    
OKR0331 10 53 43 0.93 601010 7584744
incl.     12 1.61    
OKR0341 5 129 124 0.63 600991 7584791
incl.     14 1.47    
and     4 2.20    
and     6 1.45    
and     2 3.01    
OKR0351 20 110 90 1.14 600168 7584406
incl.     55 1.37    
OKR0371 13 163 150 0.89 600976 7584836
incl.     15 2.32    
and     13 1.45    
and     23 1.23    
and     5 2.34    
OKR0381 29 55 26 0.97 600231 7584379
OKR039 35 38 3 0.83 600276 7584402
OKR0401 44 96 52 0.59 600260 7584445
incl.     9 1.06    
and     6 1.46    
OKR0411 21 231 209 0.75 600242 7584500
incl.     7 1.97    
and     15 1.15    
and     70 0.91    
OKR0421 61 117 56 1.08 600943 7584776
incl.     10 1.92    
and     15 1.34    
and 132 145 13 0.63    
OKR0431 25 192 167 0.45 600244 7584488
incl.     6 3.20    
OKR0441 12 34 22 0.52 600910 7584700
Incl. 98 101 3 1.45    
OKR0451 12 82 70 0.90 600292 7584517
incl.     7 1.89    
and     4 4.18    
and     7 2.20    
and 92 96 4 0.95    
and 158 162 4 1.29    
and 176 181 5 0.93    
OKR0461 6 92 86 0.70 600896 7584751
incl.     9 1.13    
and     7 2.00    
and     2 4.38    
and     5 1.94    
OKR0471 105 135 30 0.99 600809 7584825
incl.     6 1.93    
and     4 2.19    
OKR048 No significant intercept 600325 7584417
OKR049 No significant intercept 600369 7584437
OKR0501 63 74 11 0.47 600354 7584483
OKR0511 14 128 114 0.54 600877 7584799
incl.     13 1.61    
and     15 0.85    
and     4 1.06    
OKR0521 27 51 24 0.70 600336 7584529
incl.     7 1.16    
and     3 1.66    
and 71 88 17 0.56    
incl.     6 1.07    
OKR053 24 28 4 5.57 600380 7584547
OKR054 26 29 3 1.38 600519 7584607
OKR0551 18 47 29 1.16 600799 7584713
incl.     11 2.24    
OKR0561 27 52 25 2.00 600473 7584591
OKR0571 6 14 8 0.87 600783 7584758
and 37 78 41 1.52    
incl.     15 1.66    
and     13 2.81    
OKR0591 71 78 7 0.86 600413 7584618
and 169 173 4 0.67    
OKR0611 32 43 11 2.15 600426 7584569
OKR0621 61 126 65 0.70 600667 7584787
incl.     7 1.03    
OKR0631 42 60 18 0.70 601252 7584836
incl.     2 2.09    
and 105 111 6 1.37    
OKR0641 54 150 96 0.74 600536 7584714
incl.     5 1.08    
and     18 1.31    
and     10 1.07    
and     3 2.56    
and     3 2.12    
OKR0651 113 211 98 0.7 600650 7584835
incl.     11 1.31    
and     5 1.33    
and     12 1.41    
OKR066 83 85 2 0.80 600629 7584617
OKR0671 155 218 63 0.65 601271 7584947
incl.     15 1.06    
OKR068 87 90 3 1.28 600906 7584867
and 101 107 6 0.56    
and1 155 214 59 0.94    
incl.     9 2.28    
and     11 1.54    
OKR0691 15 39 24 1.29 600701 7584696
incl.     5 3.88    
OKR0701 19 77 58 1.04 600609 7584665
incl.     10 1.62    
and     12 1.41    
and 91 98 7 1.14    
OKR0711 47 58 11 0.72 600859 7584848
and 65 71 6 0.77    
and 116 152 36 1.04    
incl.     7 1.83    
OKR0721 50 156 106 0.54 600749 7584852
incl.     7 1.09    
and     6 1.13    
and     12 1.01    
OKR0731 39 48 9 0.70 600344 7584636
and 61 86 25 0.44    
and 93 102 9 0.57    
and 132 140 8 0.62    
and 159 186 27 0.62    
incl.     5 122    
OKR0751 20 83 62 0.63 600547 7584668
incl.     3 1.41    
and 103 105 2 2.15    
OKR076 134 137 3 1.90 600686 7584882
and1 163 220 57 0.89    
incl.     10 1.68    
OKR077 61 65 4 0.77 600399 7584500
OKR078 35 38 3 1.98 601185 7584862
and1 121 151 30 0.61    
incl.     8 1.13    
OKR0791 74 100 18 1.18 599933 7584314
OKR0801 121 220 99 0.87 600776 7584923
incl.     8 3.67    
and     3 5.15    

*
Reverse hole – drilled on azimuth of 340 degrees


1

Unconstrained
intersections
– all intercepts above 0.4g/t reported

Notes: All reported intercepts are apparent widths rounded to the nearest meter. True widths are unknown at this stage.
Total intercepts reported are unconstrained.
Included intercepts are at 0.4g/t cut-off, minimum 2m wide and no more that 2m internal dilution.
Collar positions are in UTM WGS84
surveyed by digital GPS
.

Q
ualified Person

David Underwood, BSc. (Hons) is Vice President Exploration of Osino Resources Corp. and has reviewed and approved the scientific and technical information in this news release, and is a registered Professional Natural Scientist with the South African Council for Natural Scientific Professions (Pr. Sci. Nat. No.400323/11) and a Qualified Person for the purposes of National Instrument 43-101.

Quality Assurance

All Osino sample assay results have been independently monitored through a quality assurance / quality control (“QA/QC“) program including the insertion of blind standards, blanks and duplicate samples. QA/QC samples make up 10% of all samples submitted. Logging and sampling is completed at Osino’s secure facility located in Omaruru near the Twin Hills Project. Drill core is sawn in half on site and half drill-core samples are securely transported to the Actlabs sample prep facility in Windhoek, Namibia. The core is dried, crushed to 90% -10mesh, split to 350g and pulverised to 90% -140mesh. Sample pulps are sent to Actlabs in Ontario, Canada for analysis. Gold analysis is by 30g fire assay with AA finish and automatically re-analysed with Gravimetric finish if Au >5g/t. In addition, pulps undergo 4-Acid digestion and multi-element analysis by ICP-AES or ICP-MS. RC drill samples are prepared at Actlabs sample prep facility in Windhoek, Namibia. The RC chips are dried, crushed to 90% -10mesh, split to 350g and pulverised to 90% -140mesh. Sample pulps are sent to Actlabs in Ontario, Canada for analysis. Gold analysis is by 30g fire assay with AA finish and automatically re-analysed with Gravimetric finish if Au >5g/t.

About Osino
Resources

Osino is a Canadian gold exploration company, focused on the acquisition and development of gold projects in Namibia. Having achieved our initial vision of finding Namibia’s next significant gold deposit, we are now focused on rapidly advancing the exciting Twin Hills gold discovery and to make new discoveries elsewhere along the belt. This we will achieve with Osino’s winning formula of combining innovation & drive with technical experience & strong financial backing.

Our portfolio of exclusive exploration licenses is located within Namibia’s prospective Damara mineral belt, mostly in proximity to and along strike of the producing Navachab and Otjikoto Gold Mines. Osino is targeting gold mineralization that fits the broad orogenic gold model. We are actively advancing a range of gold discoveries, prospects and targets across our approximately 7,000km2 ground position by utilizing a portfolio approach geared towards discovery.

Our core projects are favorably located north and north-west of Namibia’s capital city Windhoek. By virtue of their location, the projects benefit significantly from Namibia’s well-established infrastructure with paved highways, railway, power and water in close proximity. Namibia is mining-friendly and lauded as one of the continent’s most politically and socially stable jurisdictions. Osino continues to evaluate new ground with a view to expanding its Namibian portfolio.

Further details are available on the Company’s website at https://osinoresources.com/

CONTACT INFORMATION

Osino Resources Corp.
Heye Daun: CEO
Tel: +27 (21) 418 2525
[email protected]

Julia Becker: Investor Relations Manager
Tel: +1 (604) 785 0850
[email protected]


Cautionary Statement Regarding Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the use of proceeds from the Company’s recently completed financings, and the future plans or prospects of the Company. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”.
 
Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management, are inherently subject to business, market and economic risks, uncertainties and contingencies that may cause actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements.
 
Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information.
 
Other factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis which is available on the Company’s profile on SEDAR at
 
www.sedar.com
. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press
release.

Hyliion Reports Third Quarter 2020 Financial Results

Hyliion Reports Third Quarter 2020 Financial Results

AUSTIN, Texas–(BUSINESS WIRE)–Hyliion Holdings Corp. (NYSE: HYLN) (“Hyliion Holdings”), a leader in electrified powertrain solutions for Class 8 commercial vehicles, today reported third quarter financial results for fiscal year 2020 for Hyliion Inc. (“Hyliion”).

Key Business Highlights

  • Completed strategic combination between Hyliion Inc. and Tortoise Acquisition Corp. on October 1, 2020, yielding approximately $520 million in net proceeds to fund Hyliion’s growth plans and long-term objectives
  • Installed eight hybrid electric units in the third quarter of 2020 for four fleet-based customers
  • Signed agreement with FEV North America Inc. to accelerate commercialization of the Hypertruck ERX

Executive Commentary

“With ample resources from our strategic combination, Hyliion is well-capitalized and primed to disrupt the powertrain market. Our focus in 2020 and 2021 will be to position the company for long-term sustainable growth, capturing the material market opportunity from the electrification of class 8 vehicles. Along the way, our dynamic and proprietary solutions will help our commercial vehicle customers change the way they view performance, total cost of ownership, data, and sustainability,” commented Thomas Healy, Hyliion Holdings’ Chief Executive Officer.

“In the third quarter of 2020, we made progress toward commercialization of our Hybrid and Hypertruck ERX solutions for the Class 8 truck market, while also establishing key partnerships. We are experiencing strong interest for our solutions and are utilizing our resources to develop a scaled infrastructure that will be able to support demand from this $800 billion market. Overall, I am pleased with the progress we have made as we remain on track to meet our product milestones in 2021,” concluded Healy.

Business Impact of COVID-19

Hyliion continues to execute on its business objectives and drive growth across its platform, despite the effects of the COVID-19 pandemic on the world economy. Hyliion’s management team continues to work to advance its business objectives while maintaining the safety of its employees, suppliers, and customers. Hyliion has taken actions to mitigate issues caused by the pandemic and does not believe that those disruptions will materially impact or delay its long-term objectives.

3Q20 Conference Call

Hyliion Holdings will host a conference call and webcast for investors and other interested parties to review Hyliion’s third quarter 2020 financial results on Thursday, November 12, 2020 at 8:30 AM ET, which it will file with the Securities and Exchange Commission (the “SEC”) on Form 8-K/A. A live webcast of the call, as well as an archived replay, will be available online on the Investor Relations section of Hyliion’s website. Those wishing to participate can access the call using the links below:

Conference Call Online Registration: http://www.directeventreg.com/registration/event/5648525

Webcast: http://investors.hyliion.com/events-and-presentations

Third quarter financial results for fiscal year 2020 for Hyliion Holdings (f/k/a Tortoise Acquisition Corp.) on a standalone basis will also be filed with the SEC on Form 10-Q, and unaudited combined condensed pro formas for such period for Hyliion Holdings and Hyliion, will also be filed with the SEC under Form 8-K/A.

About Hyliion

A wholly owned subsidiary of Hyliion Holdings Corp. (NYSE: HYLN), Hyliion’s mission is to reduce the carbon intensity and greenhouse gas (GHG) emissions of commercial transportation Class 8 vehicles by being a leading provider of electrified powertrain solutions. Leveraging advanced software algorithms and data analytics capabilities, Hyliion offers fleets an easy, efficient system to decrease fuel and operating expenses while seamlessly integrating with their existing fleet operations. Headquartered in Austin, Texas, it designs, develops and sells electrified powertrain solutions that are designed to be installed on most major Class 8 commercial vehicles, with the goal of transforming the commercial transportation industry’s environmental impact at scale. For more information, visit www.hyliion.com.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of federal securities laws with respect to Hyliion Holdings and Hyliion. These forward-looking statements generally are identified by words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Such forward-looking statements include statements about Hyliion’s ability to disrupt the powertrain market, Hyliion’s focus in 2020 and 2021, the effects of Hyliion’s dynamic and proprietary solutions on its commercial vehicle customers, accelerated commercialization of the Hypertruck ERX, the ability to meet 2021 product milestones, the impact of COVID-19 on long-term objectives, and the ability to reduce carbon intensity and GHG. Hyliion Holdings undertakes no obligation, and specifically declines any obligation, except as required by law, to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the factors, risks and uncertainties regarding the Hyliion Holdings’ business described in the “Risk Factors” sections of the Hyliion Holdings’ filings with the SEC, and other factors, risks and uncertainties identified and addressed in the Hyliion Holdings’ filings with the SEC. Forward-looking statements reflect the reasonable understanding and belief of Hyliion Holdings as of the date they are made. Readers are cautioned not to put undue reliance on any forward-looking statement.

 

Hyliion Inc.

Condensed Statements of Operations

(Dollar amounts in thousands, except share and per share data)

(Unaudited)

 

Nine Months Ended September 30,

 

2020

 

 

 

2019

 

Operating expenses:

Research and development

$

(8,134

)

$

(6,716

)

Selling, general and administrative expenses

 

(3,705

)

 

(1,977

)

 

Loss from operations

 

(11,839

)

 

(8,693

)

 

Other income (expense):

Interest expense

 

(5,458

)

 

(2,176

)

Change in fair value of convertible notes payable derivative liabilities

 

(1,358

)

 

823

 

Other income

 

(12

)

 

20

 

 

Total other expense

 

(6,828

)

 

(1,333

)

 

Net loss

$

(18,667

)

$

(10,026

)

 

Cumulative dividends on convertible preferred stock

 

(1,337

)

 

(1,261

)

 

Net loss attributable to common stockholders

$

(20,004

)

$

(11,287

)

 

Net loss per share, basic and diluted

$

(0.76

)

$

(0.45

)

 

Weighted-average shares outstanding, basic and diluted

 

26,269,060

 

 

25,293,066

 

 

Hyliion Inc.

Condensed Balance Sheets

(Dollar amounts in thousands, except share and per share data)

(Unaudited)

 

 

September 30, 2020

 

December 31, 2019

Assets:

 

 

 

 

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

7,565

 

 

$

6,285

 

Accounts receivable, net

 

15

 

 

 

145

 

Prepaid expenses and other current assets

 

1,085

 

 

 

414

 

 

 

 

 

Total current assets

 

8,665

 

 

 

6,844

 

 

 

 

 

Property and equipment, net

 

1,126

 

 

 

1,635

 

Operating lease right-of-use assets

 

4,254

 

 

 

4,976

 

Intangible assets, net

 

356

 

 

429

 

Deferred transaction costs

 

4,306

 

 

 

Other assets

 

209

 

 

 

212

 

 

 

 

 

Total assets

$

18,916

 

 

$

14,096

 

 

 

 

 

Liabilities, redeemable, convertible preferred stock and stockholders’ deficit

 

 

 

 

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

4,499

 

 

$

1,156

 

Convertible notes payable derivative liabilities

 

4,745

 

 

 

3,029

 

Current portion of operating lease liabilities

 

751

 

 

 

953

 

Current portion of debt

 

28,477

 

 

 

6,720

 

Accrued expenses and other current liabilities

 

891

 

 

 

500

 

 

 

 

 

Total current liabilities

 

39,363

 

 

 

12,358

 

 

 

 

 

Operating lease liabilities, net of current portion

 

4,253

 

 

 

4,803

 

Convertible notes payable derivative liabilities, net of current portion

 

7,620

 

 

 

5,322

 

Debt, net of current portion

 

4,132

 

 

 

9,682

 

 

 

 

 

Total liabilities

 

55,368

 

 

 

32,165

 

 

 

 

 

Series A-1 redeemable, convertible preferred stock; $0.001 par value; 24,591,554 shares authorized; 22,895,580 shares issued and outstanding at September 30, 2020 and December 31, 2019 (liquidation preference of $23,812)

 

20,250

 

 

 

20,250

 

Series A-2 redeemable, convertible preferred stock; $0.001 par value; 8,793,755 shares authorized; 8,197,359 shares issued and outstanding at September 30, 2020 and December 31, 2019 (liquidation preference of $4,304)

 

3,536

 

 

 

3,536

 

Series A-3 redeemable, convertible preferred stock; $0.001 par value; 2,545,155 shares authorized; 2,328,545 shares issued and outstanding at September 30, 2020 and December 31, 2019 (liquidation preference of $2,400)

 

2,001

 

 

 

2,001

 

 

 

 

 

Total redeemable, convertible preferred stock

 

25,787

 

 

 

25,787

 

 

 

 

 

Commitments and contingencies (Note 8)

 

 

 

 

 

 

 

Stockholders’ deficit

 

 

 

Common stock, $0.001 par value; 69,817,317 shares authorized; 26,882,169 and 26,118,953 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

 

27

 

 

 

26

 

Additional paid-in capital

 

5,367

 

 

 

5,084

 

Accumulated deficit

 

(67,633

)

 

 

(48,966

)

 

 

 

 

Total stockholders’ deficit

 

(62,239

)

 

 

(43,856

)

 

 

 

 

Total liabilities, redeemable, convertible preferred stock, and stockholders’ deficit

$

18,916

 

 

$

14,096

 

 

 

 

 

Hyliion Inc.

Condensed Statements of Cash Flows

(Dollar amounts in thousands, except share and per share data)

(Unaudited)

 

Nine Months Ended September 30,

2020

2019

Operating activities:

Net loss

$

(18,667

)

$

(10,026

)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

 

665

 

 

786

 

Noncash lease expense

 

722

 

 

947

 

Paid-in-kind interest on convertible notes payable

 

1,081

 

 

428

 

Amortization of debt discount

 

4,237

 

 

1,696

 

Share-based compensation

 

165

 

 

91

 

Change in fair value of convertible notes payable derivative liabilities

 

1,358

 

 

(823

)

Change in fair value of contingent consideration liability

 

 

 

(20

)

Change in operating assets and liabilities:

Accounts receivable

 

130

 

 

41

 

Prepaid expenses and other current assets

 

(671

)

 

67

 

Other assets

 

3

 

 

106

 

Accounts payable

 

353

 

 

(927

)

Accrued expenses and other current liabilities

 

391

 

 

(246

)

Operating lease liabilities

 

(752

)

 

(458

)

 

Net cash used in operating activities

 

(10,985

)

 

(8,338

)

 

Investing activities:

 

Purchases of property and equipment

 

(105

)

 

(215

)

Proceeds from sale of property and equipment

 

22

 

 

 

 

Net cash used in investing activities

 

(83

)

 

(215

)

 

Financing activities:

Proceeds from convertible notes payable issuance and derivative liability

 

3,200

 

 

13,603

 

Proceeds from Term Loan

 

10,100

 

 

 

Proceeds from Paycheck Protection Program loan

 

908

 

 

 

Proceeds from exercise of common stock options

 

119

 

 

9

 

Payments for deferred transaction costs

 

(1,316

)

 

 

Payments for deferred financing costs

 

(468

)

 

 

Repayments on finance lease obligations

 

(195

)

 

(147

)

 

Net cash provided by financing activities

 

12,348

 

 

13,465

 

 

Net (decrease) increase in cash and cash equivalents:

 

1,280

 

 

4,912

 

Cash and cash equivalents, beginning of period

 

6,285

 

 

1,097

 

 

Cash and cash equivalents, end of period

$

7,565

 

$

6,009

 

 

INVESTOR INQUIRIES

Bob Gujavarty

Hyliion Holdings

[email protected]

MEDIA RELATIONS

Mustafa Riffat

[email protected]

Jeremy Cohen

[email protected]

Edelman

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Alternative Vehicles/Fuels Other Transport Technology Trucking Automotive Transport Other Automotive Software Data Management Logistics/Supply Chain Management

MEDIA:

Logo
Logo

Temporary Jobs Providing Crucial Safety Net in COVID Economy, PeopleReady Survey Finds

Temporary Jobs Providing Crucial Safety Net in COVID Economy, PeopleReady Survey Finds

More than half of people taking temporary jobs have been affected by job loss, full-time employment elusive for many

TACOMA, Wash.–(BUSINESS WIRE)–
As job loss continues to grip the nation and the full-time permanent job market struggles to recover, temporary jobs are proving to be a safety net for many people across the country, according to a new survey from staffing leader PeopleReady.

The PeopleReady survey found that 51% of those taking temporary jobs have experienced job loss (either themselves or a household member) in the past month, and 78% of them are also looking for a full-time permanent job but having difficulty finding one (67%). The overwhelming majority of respondents (79%) said that income from temporary jobs has become critical in maintaining their household budgets since the economic downturn.

“The full-time job market will take time to recover. Following an economic downturn, temporary jobs tend to return to the marketplace sooner,” said Taryn Owen, president of PeopleReady. “Temporary jobs are available now to connect people to work. Whether someone is out of work or looking to earn more money over the holidays, temporary employment can help.”

While the majority of respondents (67%) reported having more difficulty paying their bills since the economic downturn, nearly all of them (99%) said they rely on income from temporary work to pay for everyday household expenses, including rent or mortgage payments (43%), utility bills (15%), groceries (15%), car payments (7%), and other living costs (20%).

If they were unable to work, respondents reported their savings would last: one week or less (21%), 2–3 weeks (13%), 1–2 months (16%), 3–5 months (8%), 6–11 months (4%), a year or longer (4%). Many said they had no personal savings at all (35%).

“Job seekers who are struggling to find the kinds of full-time jobs they lost may want to consider a different approach,” added Owen. “Temporary jobs can help them bridge employment gaps, build new skills, and establish relationships with potential employers—all while providing much-needed income.”

PeopleReady has a variety of ways for job seekers to access potential job opportunities: via app (JobStack), online (www.jobs.peopleready.com), and in person (at all PeopleReady branches across the nation).

Survey Methodology

A SurveyMonkey survey of 1,749 temporary workers was conducted by PeopleReady between Sept. 7, 2020, and Nov. 6, 2020.

About PeopleReady

PeopleReady, a TrueBlue company (NYSE: TBI), specializes in quick and reliable on-demand labor and highly-skilled workers. PeopleReady supports a wide range of blue-collar industries, including construction, manufacturing and logistics, waste and recycling, and hospitality. Leveraging its game-changing JobStack platform, PeopleReady serves more than 130,000 businesses and puts more than 300,000 people to work each year, operating more than 600 branch offices across all 50 states, Puerto Rico, and Canada. Learn more at www.peopleready.com.

Media Contact

David Irwin

PeopleReady Communications Director

[email protected]

630-453-1120

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Women Consumer Professional Services Men Human Resources

MEDIA:

Logo
Logo